Recordati Industria Chimica E Farmaceutica S.P.A. (RCDTF)
(Delayed Data from OTC)
$52.25 USD
0.00 (0.00%)
Updated Aug 1, 2024 02:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Recordati Industria Chimica E Farmaceutica SPA falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 252 | 325 | 303 | 8 | 222 |
Receivables | 589 | 449 | 417 | 361 | 422 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 438 | 447 | 271 | 287 | 254 |
Other Current Assets | 22 | 16 | 15 | 12 | 9 |
Total Current Assets | 1,301 | 1,237 | 1,006 | 883 | 906 |
Net Property & Equipment | 193 | 168 | 155 | 152 | 149 |
Investments & Advances | 23 | 30 | 40 | 52 | 43 |
Other Non-Current Assets | 0 | 13 | 0 | 0 | 0 |
Deferred Charges | 83 | 81 | 90 | 86 | 80 |
Intangibles | 2,940 | 2,674 | 2,002 | 1,917 | 1,949 |
Deposits & Other Assets | 13 | 10 | 39 | 8 | 18 |
Total Assets | 4,554 | 4,213 | 3,332 | 3,098 | 3,146 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 108 | 88 | 10 | 14 | 15 |
Accounts Payable | 286 | 237 | 211 | 151 | 197 |
Current Portion Long-Term Debt | 385 | 307 | 264 | 309 | 168 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 73 | 35 | 35 | 34 | 24 |
Other Current Liabilities | 234 | 306 | 222 | 153 | 254 |
Total Current Liabilities | 1,086 | 973 | 741 | 661 | 657 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 156 | 177 | 32 | 47 | 48 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1,465 | 1,413 | 900 | 889 | 1,050 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 23 | 20 | 25 | 43 | 48 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,729 | 2,584 | 1,697 | 1,640 | 1,803 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 28 | 28 | 31 | 30 | 29 |
Capital Surplus | 91 | 88 | 99 | 96 | 94 |
Retained Earnings | 2,192 | 1,935 | 1,966 | 1,720 | 1,533 |
Other Equity | -348 | -264 | -311 | -288 | -208 |
Treasury Stock | 139 | 158 | 150 | 100 | 105 |
Total Shareholder's Equity | 1,825 | 1,629 | 1,635 | 1,458 | 1,343 |
Total Liabilities & Shareholder's Equity | 4,554 | 4,213 | 3,332 | 3,098 | 3,146 |
Total Common Equity | 1,825 | 1,629 | 1,635 | 1,458 | 1,343 |
Shares Outstanding | NA | 206.30 | 206.30 | NA | 209.10 |
Book Value Per Share | -0.02 | 7.90 | 7.92 | -0.01 | 6.42 |
Fiscal Year End for Recordati Industria Chimica E Farmaceutica SPA falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 334 | 252 | 349 | -99,999 |
Receivables | NA | 631 | 589 | 519 | NA |
Notes Receivable | NA | 0 | 0 | NA | NA |
Inventories | NA | 432 | 438 | 437 | NA |
Other Current Assets | NA | 41 | 22 | 26 | NA |
Total Current Assets | NA | 1,438 | 1,301 | 1,332 | NA |
Net Property & Equipment | NA | 194 | 193 | 188 | NA |
Investments & Advances | NA | 27 | 23 | 22 | NA |
Other Non-Current Assets | NA | 0 | 0 | NA | NA |
Deferred Charges | NA | 85 | 83 | 86 | NA |
Intangibles | NA | 2,890 | 2,940 | 2,959 | NA |
Deposits & Other Assets | NA | 14 | 13 | 19 | NA |
Total Assets | NA | 4,648 | 4,554 | 4,606 | NA |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 37 | 108 | 45 | NA |
Accounts Payable | NA | 313 | 286 | 275 | NA |
Current Portion Long-Term Debt | NA | 403 | 385 | 432 | NA |
Current Portion Capital Leases | NA | 0 | 0 | NA | NA |
Accrued Expenses | NA | 0 | 0 | NA | NA |
Income Taxes Payable | NA | 84 | 73 | 77 | NA |
Other Current Liabilities | NA | 220 | 234 | 211 | NA |
Total Current Liabilities | NA | 1,057 | 1,086 | 1,040 | NA |
Mortgages | NA | 0 | 0 | NA | NA |
Deferred Taxes/Income | NA | 152 | 156 | 168 | NA |
Convertible Debt | NA | 0 | 0 | NA | NA |
Long-Term Debt | NA | 1,443 | 1,465 | 1,499 | NA |
Non-Current Capital Leases | NA | 0 | 0 | NA | NA |
Other Non-Current Liabilities | NA | 23 | 21 | NA | |
Minority Interest (Liabilities) | NA | 0 | 0 | NA | NA |
Total Liabilities | NA | 2,675 | 2,729 | 2,728 | NA |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | NA | NA |
Common Stock (Par) | NA | 28 | 28 | 28 | NA |
Capital Surplus | NA | 91 | 91 | 91 | NA |
Retained Earnings | NA | 2,347 | 2,192 | 2,109 | NA |
Other Equity | NA | -367 | -348 | -213 | NA |
Treasury Stock | NA | 125 | 139 | 138 | NA |
Total Shareholder's Equity | NA | 1,973 | 1,825 | 1,878 | NA |
Total Liabilities & Shareholder's Equity | NA | 4,648 | 4,554 | 4,606 | NA |
Total Common Equity | 0 | 1,973 | 1,825 | 101,877 | 0 |
Shares Outstanding | NA | NA | NA | NA | NA |
Book Value Per Share | 0.00 | -0.02 | -0.02 | -1.02 | 0.00 |